Bronstein, Gewirtz & Grossman, LLC announces a class action lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA) and certain officers for alleged violations of federal securities laws related to the company's September 2024 IPO. The lawsuit cites BioAge’s announcement on December 6, 2024, of the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which caused the stock price to plummet from $20.09 to $4.65 per share. Investors who suffered losses are encouraged to join the lawsuit before the March 10, 2025, lead plaintiff deadline.